[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100423872":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":10,"locations":25,"responsibleParty":46,"collaborators":48,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational (ultrasound)",null,"AIM 1: Participants undergo a breast ultrasound over 15 minutes.\n\nAIM 2: Participants undergo breast ultrasounds over 15 minutes before starting the chemotherapy and\u002For endocrine therapy, 2 months after start of chemotherapy and\u002For endocrine therapy, and after the completion of chemotherapy and\u002For endocrine therapy before surgery. Participants may also undergo breast ultrasounds at 2 weeks after start of chemotherapy and\u002For endocrine therapy and 1 month after start of chemotherapy and\u002For endocrine therapy.\n\nAIM 3: Patients with suspicious breast masses or known breast cancer who are scheduled for axillary lymph node biopsy undergo ultrasound over 15 minutes at the same visit of the breast mass study.",[13],"Procedure: Ultrasound",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Ultrasound","Undergo breast ultrasound",[9],[21],{"name":22,"affiliation":23,"role":24},"Azra Alizad, M.D.","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[26],{"facility":23,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-92.4699,44.02163,{"lat":37,"lon":36},[40,45],{"name":41,"role":42,"phone":43,"phoneExt":10,"email":44},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",{"name":22,"role":24,"phone":10,"phoneExt":10,"email":10},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[49],{"name":50,"class":51},"National Cancer Institute (NCI)","NIH","100423872","quantitative-microvasculature-imaging-for-breast-cancer-detection-and-monitoring-100423872",false,"NCT04799535","Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring","Inclusion Criteria:\n\n* AIM 1: Patient volunteers, ages \\>= 18 with suspicious breast masses scheduled for breast biopsy, or at least two weeks or more after breast biopsy\n* AIM 2: Patient volunteers, ages \\>= 18 who have biopsy proven breast cancer and are going under neoadjuvant chemotherapy and\u002For endocrine therapy had their baseline MRI and\u002For ultrasound\n\nExclusion Criteria:\n\n* Patients with breast implants or any condition that does not allow proper use of ultrasound (US)","ALL","18 Years",{"count":61,"type":62},550,"ESTIMATED","OBSERVATIONAL","This study evaluates the effectiveness of a breast ultrasound method for the diagnosis of breast cancer. Diagnostic procedures, such as breast ultrasound, may help find and diagnose breast cancer, and may help measure a patient's response to earlier treatment. The purpose of this research is to test the effectiveness of a new investigational breast ultrasound method to detect an abnormality in the breast, and assess response to breast cancer treatment.",[66,67],"Breast Carcinoma","Breast Neoplasm","2026-01-30",{"date":70,"type":71},"2026-02-03","ACTUAL",{"date":73,"type":71},"2019-09-01",{"date":75,"type":62},"2027-11-29",{"name":5,"class":6},1]